Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RG-7388 (Nova Southeastern Univ.): sourced facts only. name: "This study investigated the therapeutic efficacy of the MDM2 inhibitor (RG-7388), the dual DNMT1/G9a inhibitor (CM-272), and the DNMT inhibitor (SGI-1027) in an SK-N-AS xenograft mouse model." [DOI:10.1158/1538-7445.am2026-7066]; target: "This study investigated the therapeutic efficacy of the MDM2 inhibitor (RG-7388), the dual DNMT1/G9a inhibitor (CM-272), and the DNMT inhibitor (SGI-1027) in an SK-N-AS xenograft mouse model." [DOI:10.1158/1538-7445.am2026-7066]; developer: "Barry and Judy Silverman College of Pharmacy, Nova Southeastern University, Fort Lauderdale, FL." [DOI:10.1158/1538-7445.am2026-7066]; stage: "Interestingly, treatment with RG-7388 also induced potent tumor suppression but exhibited a less durable response compared to CM-272." [DOI:10.1158/1538-7445.am2026-7066]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on RG-7388 (Nova Southeastern Univ.).